Stonepine Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA

Stonepine Capital Management LLC purchased a new stake in ImageneBio, Inc. (NASDAQ:IMA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 96,172 shares of the company’s stock, valued at approximately $539,044,000.

Other large investors also recently modified their holdings of the company. Barclays PLC grew its position in shares of ImageneBio by 170.8% during the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after buying an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of ImageneBio during the 4th quarter valued at $76,000. Millennium Management LLC acquired a new position in shares of ImageneBio during the 4th quarter valued at $79,000. T3 Companies LLC bought a new position in ImageneBio during the fourth quarter worth $91,000. Finally, Jane Street Group LLC bought a new position in ImageneBio during the fourth quarter worth $103,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. HC Wainwright started coverage on ImageneBio in a research note on Friday, August 21st. They issued a “buy” rating and a $28.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $29.00.

ImageneBio Trading Down 1.8%

IMA opened at $5.33 on Friday. The company’s fifty day moving average price is $5.77 and its two-hundred day moving average price is $5.81. ImageneBio, Inc. has a 1-year low of $3.94 and a 1-year high of $13.98. The company has a market cap of $60.50 million, a price-to-earnings ratio of -1.16 and a beta of 0.76.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. As a group, equities analysts forecast that ImageneBio, Inc. will post -3.23 earnings per share for the current fiscal year.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.